# Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

> **NCT06569524** · PHASE2 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Non-alcoholic Steatohepatitis

## Interventions

- **DRUG:** TQA2225/AP025 or TQA2225/AP025 Placebo 25mg
- **DRUG:** TQA2225/AP025 or TQA2225/AP025 Placebo 50mg

## Key facts

- **NCT ID:** NCT06569524
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-14
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06569524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06569524, "Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06569524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*